04:33 PM EDT, 09/05/2025 (MT Newswires) -- DIAGNOS ( DGNOF ) , an AI-based health-technology company, on Friday said it closed of a non-brokered private placement of convertible-debenture units.

The company will issue 10 units priced at $10,000 each, with proceed earmarked to fund product development, commercialization of AI-based screening services, as well as general and administrative expenses.

Each unit consists of an unsecured convertible debenture and 10,000 share warrants. Each debenture has a term of 12 months ending September 5, 2026, and bears an annual interest rate of 10% payable in cash on a semi-annual basis.

The holder of the debenture is also entitled to convert the principal amount at any time during the term into shares at $0.28 per share. Each warrant entitles the holder to purchase a share at $0.40 per share at any time during the term.

DIAGNOS ( DGNOF ) shares closed $0.01 to $0.27 on the TSX Venture Exchange.